Below are citations regarding blood-based biomarkers (BBMs) in neurodegenerative research.
Burnham, S. C., Harper, L., Locascio, T., McPherson, H. E., Pontecorvo, M., & Wang, J. (2025). Evaluating the interchangeability of blood based biomarkers and amyloid PET for identifying patients with Alzheimer’s pathology. Alzheimer’s & Dementia, 20(Suppl 2), e091465. https://doi.org/10.1002/alz.091465
Burns J. M., Morris, J. K, Vidoni, E. D., Townley, R. A, Gillen L. R., Smith T. R., Jones, J. E., Nelson M. B., Mudaranthakam D. P, Perales-Puchalt, J, Lewandowsk T., Niedens C. M., Parks, A. C., Brunette A. M., Aschenbrenner A. J, I. B. Taylor, Forcino R. C., Woodward, J. L. (2026) Brain health care accelerator: A primary care–centered model for scaling dementia diagnosis and care. Alzheimer’s & Dementia, 22 (Issue 4), e71405. https://doi.org/10.1002/alz.71405
Jannati, A., Thompson, K., Toro-Serey, C., Gomes-Osman, J., Banks, R. E., Higgins, C., Showalter, J., Bates, D., Tobyne, S., & Pascual-Leone, A. (2025). Concurrent detection of cognitive impairment and amyloid positivity with a multimodal machine learning-enabled digital cognitive assessment. Alzheimer’s research & therapy, 17(1), 261. https://doi.org/10.1186/s13195-025-01913-5
KU Alzheimer’s Disease Research Center. (27 March 2025). Alzheimer’s Blood Based Biomarkers Primary Care – All Modules (13 minutes). [Playlist]. Youtube. https://www.youtube.com/playlist?list=PLpOGWtddQeyoFPH6KZv8f7TYudcNLgwbZ.
Office. (2025). FDA Clears First Blood Test Used in Diagnosing Alzheimer’s Disease. U.S. Food and Drug Administration. https://www.fda.gov/news-events/press-announcements/fda-clears-first-blood-test-used-diagnosing-alzheimers-disease
PeerView Live. (2026).The Science and Promise of Blood-Based Biomarkers in Alzheimer’s Disease.[Powerpoint Slides].
Russell A, Vogeley A, Lovett R, O’Conor R, Batio S, Hurtado J, Bonham M, Yoshino Benavente J, Brickman A. M., Williamson J. D., Udeh-Momoh C., Mielke M. M., Wolf M. (2026) Patient views on blood-based biomarker tests for Alzheimer’s disease in primary care. Alzheimer’s & Dementia, 22 (Issue 4),e71247 https://doi.org/10.1002/alz.71247
Schindler, Suzanne. (2026, February).Important update regarding the CMS Alzheimer’s disease Registry! For Medicare beneficiaries receiving amyloid-targeted therapies, clinicians report how amyloid pathology was confirmed. [Description]. [Post]. LinkedIn. https://www.linkedin.com/posts/suzanne-schindler-69781050_important-update-regarding-the-cms-alzheimer-activity-7432087215641440256-5F1A/utm_source=social_share_send&utm_medium=member_desktop_web&rcm=ACoAAAeYE3kBD4RlTxgMr3o0jAqXEH8JAirbpM
Whitson, H. E., Fowler, N. R., & Mielke, M. M. (2026). Blood-Based Biomarkers for Alzheimer Disease: Preventing Unintended Consequences. JAMA, 335(8), 663–664. https://doi.org/10.1001/jama.2025.26049 [Can also be accessed on the NIH].